drugset / Trial / NCT03958955

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

NCT03958955

Phase 2 Terminated 27 enrolled LEO Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

This was a double-blind, multi-centre, randomised, vehicle-controlled, within-subject phase 2a trial. The trial was designed to establish the efficacy and safety of delgocitinib cream in the treatment of adult subjects with discoid lupus erythematosus (DLE).

Timeline

Start
2019-07-09
Primary completion
2020-04-15
Completion
2020-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Delgocitinib Small molecule 20 unknown Topical